177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Key Points

Key points are not available for this paper at this time.

Abstract

PSMA RLT with (177)Lu-PSMA is feasible, safe, and effective in end-stage progressive mCRPC with appropriate selection and follow-up of patients by (68)Ga-PSMA PET/CT through application of the concept of theranostics.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Journals

Journal of Nuclear Medicine

Institutions

Technical University of Munich

Zentralklinik Bad Berka

References and Citations

Add This Paper to Your Research Feed

Any time a new paper drops it will be there.